Projects

« zurück zur Übersicht

BioVersys GmbH ETH Zürich Marc Gitzinger Bacterial transcriptional regulators, which initiate bacterial defense mechanisms causing drug resistance. BioVersys GmbH is a Swiss biopharmaceutical company that focuses on research and development of new drugs and compounds, which switch-off drug resistance within the pathogen and render antibiotics effective again. Being an ETH-Zurich spin-off company we rely on our profound technological expertise, that is reflected by numerous patents and publications.

Milestones

	Datum	Beschreibung
	27.05.2009	BioVersys gets the "Kick" and was selected to win 100.000 Sfr at Venture Kick Stage III
	18.03.2009	Dr. Wilfried Weber and BioVersys win the Swiss TB award
	19.09.2008	Incorporation of BioVersys GmbH
	04.06.2008	BioVersys receives KTI/CTI coachting acceptance

 

Dokumente

Beschreibung

entrepreneurial ID

 

Links

Internet: News
Internet: Pipeline and Research
Internet: Press